{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:55:44Z","timestamp":1785902144944,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["10\/248"],"award-info":[{"award-number":["10\/248"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2259-2","type":"journal-article","created":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T07:46:46Z","timestamp":1487576806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity"],"prefix":"10.1186","volume":"17","author":[{"given":"Andrea M.","family":"Teng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgi","family":"Kvizhinadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,20]]},"reference":[{"issue":"2","key":"2259_CR1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ijc.28999","volume":"136","author":"M Plummer","year":"2015","unstructured":"Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. International journal of cancer Journal international du cancer. 2015;136(2):487\u201390.","journal-title":"International journal of cancer Journal international du cancer"},{"key":"2259_CR2","first-page":"CD005583","volume":"7","author":"AC Ford","year":"2015","unstructured":"Ford AC, Forman D, Hunt R, Yuan Y, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. The Cochrane Library. 2015;7:CD005583.","journal-title":"The Cochrane Library"},{"issue":"10","key":"2259_CR3","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1440-1746.2009.05982.x","volume":"24","author":"KM Fock","year":"2009","unstructured":"Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY. Second Asia\u2013Pacific consensus guidelines for helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24(10):1587\u2013600.","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"2259_CR4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1155\/2004\/326767","volume":"18","author":"M Richard Hunt","year":"2004","unstructured":"Richard Hunt M, Carlo Fallone M, Sander Veldhuyzan van Zanten M, Phil Sherman M. Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori\u2013an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. Can J Gastroenterol. 2004;18(9):547.","journal-title":"Can J Gastroenterol"},{"key":"2259_CR5","volume-title":"Working Group Report","author":"International Agency for Research on Cancer, World Health Organization","year":"2014","unstructured":"International Agency for Research on Cancer, World Health Organization. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. In: Working Group Report, vol. 8. Lyon: International Agency for Research on Cancer; 2014."},{"key":"2259_CR6","doi-asserted-by":"crossref","first-page":"g3174","DOI":"10.1136\/bmj.g3174","volume":"348","author":"AC Ford","year":"2014","unstructured":"Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.","journal-title":"BMJ"},{"key":"2259_CR7","doi-asserted-by":"crossref","unstructured":"Harris RA, Owens DK, Witherell H, Parsonnet J: Helicobacter pylori and Gastric Cancer: What Are the Benefits of Screening Only for the CagA Phenotype of H. pylori? Helicobacter. 1999;4(2):69-75.","DOI":"10.1046\/j.1523-5378.1999.98057.x"},{"issue":"9021","key":"2259_CR8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(96)01501-2","volume":"348","author":"J Parsonnet","year":"1996","unstructured":"Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. The Lancet. 1996;348(9021):150\u20134.","journal-title":"The Lancet"},{"issue":"1","key":"2259_CR9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1017\/S0266462307080117","volume":"24","author":"F Xie","year":"2008","unstructured":"Xie F, Luo N, Blackhouse G, Goeree R, Lee HP. Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese. Int J Technol Assess Health Care. 2008;24(1):87\u201395.","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"2259_CR10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/hel.12185","volume":"20","author":"HC Cheng","year":"2015","unstructured":"Cheng HC, Wang JD, Chen WY, Chen CW, Chang SC, Sheu BS. Helicobacter pylori test-and-treat program can be cost-effective to prevent gastric cancer in Taiwanese adults: referred to the nationwide reimbursement database. Helicobacter. 2015;20(2):114\u201324.","journal-title":"Helicobacter"},{"issue":"5","key":"2259_CR11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacr.2009.01.022","volume":"6","author":"F Xie","year":"2009","unstructured":"Xie F, O\u2019Reilly D, Ferrusi IL, Blackhouse G, Bowen JM, Tarride JE, Goeree R. Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada. J Am Coll Radiol. 2009;6(5):317\u201323.","journal-title":"J Am Coll Radiol"},{"issue":"5","key":"2259_CR12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/1055-9965.EPI-06-0758","volume":"16","author":"YC Lee","year":"2007","unstructured":"Lee YC, Lin JT, Wu HM, Liu TY, Yen MF, Chiu HM, Wang HP, Wu MS, Hsiu-Hsi Chen T. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(5):875\u201385.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2259_CR13","doi-asserted-by":"crossref","unstructured":"Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Bhandari P, Patel P: The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess. 2003;7(6):1-86.","DOI":"10.3310\/hta7060"},{"issue":"9","key":"2259_CR14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s10552-011-9804-x","volume":"22","author":"T Blakely","year":"2011","unstructured":"Blakely T, Shaw C, Atkinson J, Cunningham R, Sarfati D. Social inequalities or inequities in cancer incidence? Repeated census-cancer cohort studies, New Zealand 1981-1986 to 2001-2004. Cancer causes & control. 2011;22(9):1307\u201318.","journal-title":"Cancer causes & control"},{"key":"2259_CR15","doi-asserted-by":"crossref","unstructured":"\u200bTeng AM, Blakely T, Baker MG, Sarfati D. The contribution of Helicobacter pylori to excess gastric cancer in Indigenous and Pacific men: a birth cohort estimate. Gastric Cancer. 2016:1-4. Accessed July 2015.","DOI":"10.1007\/s10120-016-0671-8"},{"key":"2259_CR16","unstructured":"Fraser A. Treatment for Helicobacter infection in New Zealand: A discussion document.\u00a0In: Gastroenterology NZSoG: New Zealand Society of Gastroenterology; 2013."},{"key":"2259_CR17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/archinte.159.2.142","volume":"159","author":"AM Fendrick","year":"1999","unstructured":"Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and Economic Effects of Population-Based Helicobacter pylori Screening to Prevent Gastric Cancer. Arch Intern Med. 1999;159:142\u20138.","journal-title":"Arch Intern Med"},{"key":"2259_CR18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1046\/j.1365-2036.2002.01204.x","volume":"16","author":"J Mason","year":"2002","unstructured":"Mason J, Axon ATR, Forman D, Duffett S, Drummond M, Crocombe W, Feltbower R, Mason S, Brown J, Moayyedi P. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomised trial. Aliment Pharmacol Ther. 2002;16:559\u201368.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2259_CR19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ijc.23864","volume":"124","author":"JM Yeh","year":"2009","unstructured":"Yeh JM, Kuntz KM, Ezzati M, Goldie SJ. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer. 2009;124(1):157\u201366.","journal-title":"Int J Cancer"},{"key":"2259_CR20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1523-5378.2009.00672.x","volume":"14","author":"T Shimoyama","year":"2009","unstructured":"Shimoyama T, Oyama T, Matsuzaka M, Danjo K, Nakaji S, Fukuda S. Comparison of a Stool Antigen Test and Serology for the Diagnosis of Helicobacter pylori Infection in Mass Survey. Helicobacter. 2009;14:87\u201390.","journal-title":"Helicobacter"},{"key":"2259_CR21","volume-title":"Public Health Monograph","author":"R Costilla","year":"2011","unstructured":"Costilla R, Atkinson J, Blakely T. Incoporating Ethnic and Deprivation Variation to Cancer Incidence Estimates over 2006-2026 for ABC-CBA. In: Public Health Monograph, vol. 19. Wellington: University of Otago; 2011. Burden of Disease Epidemiology Equity and Cost-Effectiveness Programme (BODE3), vol. Technical Report Number 5."},{"key":"2259_CR22","volume-title":"Cancer incidence in five continents","author":"D Forman","year":"2013","unstructured":"Forman D, Bray F, Brewster D, Gombe Mbalawa C, Kohler B, Pi\u00f1eros M, et al. Cancer incidence in five continents. Lyon: International Agency for Research on Cancer; 2013."},{"key":"2259_CR23","unstructured":"New Zealand Period Life Tables: 2010-2012. [ http:\/\/www.stats.govt.nz\/browse_for_stats\/health\/life_expectancy\/NZLifeTables_HOTP10-12.aspx ]. Accessed July 2015."},{"key":"2259_CR24","volume-title":"Cancer Excess Mortality Rates Over 2006-2026 for ABC-CBA","author":"T Blakely","year":"2012","unstructured":"Blakely T, Costilla R, Soeberg M. Cancer Excess Mortality Rates Over 2006-2026 for ABC-CBA. Wellington: University of Otago; 2012."},{"issue":"9859","key":"2259_CR25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","volume":"380","author":"JA Salomon","year":"2010","unstructured":"Salomon JA, Vos T, Hogan DR. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2010;380(9859):2129\u201343.","journal-title":"Lancet"},{"key":"2259_CR26","volume-title":"Health Loss in New Zealand: A Report from the New Zealand Burden of Diseases, Injuries, and Risk Factors Study, 2006-2016","author":"Ministry of Health","year":"2013","unstructured":"Ministry of Health. Health Loss in New Zealand: A Report from the New Zealand Burden of Diseases, Injuries, and Risk Factors Study, 2006-2016. Wellington: Ministry of Health; 2013."},{"key":"2259_CR27","unstructured":"Trendly Beta: Promoting High Performance in Health [ http:\/\/trendly.co.nz\/Home\/DHBIndicatorSummaryReport ]. Accessed July 2015."},{"key":"2259_CR28","unstructured":"The changing face of Helicobacter pylori testing [ http:\/\/www.bpac.org.nz\/BT\/2014\/May\/h-pylori.aspx ]. Accessed July 2015."},{"issue":"1384","key":"2259_CR29","first-page":"64","volume":"126","author":"J Hsiang","year":"2013","unstructured":"Hsiang J, Selvaratnam S, Taylor S, Yeoh J, Tan Y-M, Huang J, Patrick A. Increasing primary antibiotic resistance and ethnic differences in eradication rates of Helicobacter pylori infection in New Zealand\u2014a new look at an old enemy. New Zealand Medical Journal. 2013;126(1384):64\u201376.","journal-title":"New Zealand Medical Journal"},{"key":"2259_CR30","doi-asserted-by":"crossref","unstructured":"Li WQ, Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX et al: Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst. 2014, 106(7). Accessed July 2015.","DOI":"10.1093\/jnci\/dju116"},{"key":"2259_CR31","unstructured":"PPPs and exchange rates: Purchasing Power Parities for GDP [ https:\/\/stats.oecd.org\/Index.aspx?DataSetCode=SNA_TABLE4 #]. Accessed July 2015."},{"key":"2259_CR32","unstructured":"Prices and purchasing power parities (PPP): new international comparisons of GDP and consumption based on purchasing power parities for the year 2011 [ http:\/\/www.oecd.org\/std\/prices-ppp\/ppps-2011-benchmark-year.htm ]. Accessed July 2015."},{"key":"2259_CR33","volume-title":"Public Health Monograph","author":"T Blakely","year":"2012","unstructured":"Blakely T, Foster R, Wilson N. Public Health Monograph, vol. 30. Wellington: University of Otago; 2012. Burden of Disease Epidemiology Equity and Cost-Effectiveness Programme (BODE3)."},{"key":"2259_CR34","volume-title":"Public Health Monograph","author":"R Foster","year":"2013","unstructured":"Foster R, Blakely T, Wilson N, O\u2019Dea D. Protocol for Direct Costing of Health Sector Interventions for Economic Modelling (Including Event Pathways). In: Public Health Monograph, vol. 27. Wellington: University of Otago; 2013. Burden of Disease Epidemiology Equity and Cost-Effectiveness Programme (BODE3)."},{"key":"2259_CR35","volume-title":"Public Health Monograph","author":"R Foster","year":"2011","unstructured":"Foster R, Preval N. Costing of pharmaceuticals in New Zealand for health economic studies: backgrounder and protocol for costing. In: Public Health Monograph, vol. 20. Wellington: University of Otago; 2011. Burden of Disease Epidemiology Equity and Cost-Effectiveness Programme (BODE3)."},{"issue":"5","key":"2259_CR36","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","volume":"57","author":"KA Brown","year":"2013","unstructured":"Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57(5):2326\u201332.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2259_CR37","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1053\/j.gastro.2005.09.016","volume":"129","author":"AC Ford","year":"2005","unstructured":"Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology. 2005;129(6):1910\u20137.","journal-title":"Gastroenterology"},{"key":"2259_CR38","unstructured":"National Health Committee: Screening to Improve Health in New Zealand: Criteria to assess screening programmes. In. Wellington: Ministry of Health; 2003.\u00a0 https:\/\/www.nsu.govt.nz\/publications\/screening-improve-health-new-zealand-criteria-assess-screening-programmes ."},{"issue":"6","key":"2259_CR39","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.bpg.2014.10.003","volume":"28","author":"R Herrero","year":"2014","unstructured":"Herrero R, Park JY, Forman D. The fight against gastric cancer - the IARC Working Group report. Best Pract Res Clin Gastroenterol. 2014;28(6):1107\u201314.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2259_CR40","doi-asserted-by":"crossref","first-page":"g3320","DOI":"10.1136\/bmj.g3320","volume":"348","author":"AC Ford","year":"2014","unstructured":"Ford AC, Moayyedi P. Whom should we \u201ctest and treat\u201d for Helicobacter pylori? BMJ. 2014;348:g3320.","journal-title":"BMJ"},{"issue":"2","key":"2259_CR41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/hel.12186","volume":"20","author":"AM McDonald","year":"2015","unstructured":"McDonald AM, Sarfati D, Baker MG, Blakely T. Trends in Helicobacter pylori infection among Maori, Pacific, and European Birth cohorts in New Zealand. Helicobacter. 2015;20(2):139\u201345.","journal-title":"Helicobacter"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2259-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T06:56:30Z","timestamp":1498373790000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2259-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,20]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2259"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2259-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,20]]},"article-number":"156"}}